ARDX DEADLINE: SueWallSt Reminds Ardelyx, Inc. Investors of Upcoming Securities Class Action Deadline
Alert: Claims focus on alleged misrepresentations about payer utilization management and prescription pull-through, which allegedly slowed new-patient starts for IBSRELA while Ardelyx reaffirmed $240 million to $250 million in 2025 sales guidance. NEW YORK, Oct. 29, 2026 /PRNewswire/ --...